Zusammenfassung
Die Bedeutung der konventionellen nuklearmedizinischen Diagnostik von Raumforderungen
der Leber hat mit der Entwicklung neuer Bildgebungsprotokolle in der Sonographie,
Computertomographie (CT) und Magnetresonanz-Tomographie (MRT) eine deutliche Wandlung
erfahren. Mit der Positronen-Emissions-Tomographie (PET) steht ein Verfahren zur Verfügung,
welches eine gewebe- und funktionsspezifische Charakterisierung in Ergänzung zu den
modernen, morphologischen Verfahren erlaubt und somit prinzipiell zur Dignitätsbeurteilung
bekannter Leberläsionen geeignet ist. Die vorliegende Übersicht beschreibt den gegenwärtigen
Stellenwert der nuklearmedizinischen Diagnostik inklusive PET für die Diagnostik fokaler
Leberläsionen unter besonderer Berücksichtigung der klinischen Anwendung verschiedener
Untersuchungsverfahren im klinischen Kontext.
Abstract
With the introduction of new imaging protocols for ultrasound, computed tomography
(CT) and magnetic resonance imaging (MRI), the importance of conventional nuclear
medicine diagnostic procedures has changed fundamentally. With the introduction of
positron emission tomography (PET) into routine diagnostics, the assessment of tissue-specific
function adds on to the modern, morphological imaging procedures and in principle
allows for differentiating benign from malignant lesions. The actual clinical value
of nuclear medicine procedures for the diagnostic workup of focal liver lesions is
discussed.
Schlüsselwörter
Leberrundherd - kavernöses Hämangiom - FNH - HCC - Lebermetastase
Key words
Liver Lesions - Cavernous Hemangioma - FNH - HCC - Liver Metastasis
Literatur
- 1
Bonanno N, Baldari S, Cerrito A, Zimbaro G, Restifo G, Blandino A, Freni O.
Diagnosis of hepatic hemangiomas with 99mTc-labeled red blood cell scanning: value of SPECT.
J Nucl Biol Med.
1991;
35
135-140
- 2
Brant W E, Floyd J L, Jackson D E, Gilliland J D.
The radiological evaluation of hepatic cavernous hemangioma.
Jama.
1987;
257
2471-2474
- 3
Calvet X, Pons F, Bruix J, Bru C, Lomena F, Herranz R, Brugera M, Faus R, Rodes J.
Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma:
relationship between detectability and tumor differentiation.
J Nucl Med.
1988;
29
1916-1920
- 4
Diederichs C G, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs H J, Beger H G,
Reske S N.
Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with
preoperative evaluation of patients with pancreatic masses.
Pancreas.
2000;
20
109-116
- 5
Dose J, Bleckmann C, Bachmann S, Bohuslavizki K H, Berger J, Jenicke L, Habermann C R,
Janicke F.
Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic
procedures” for the detection of distant metastases in breast cancer patients.
Nucl Med Commun.
2002;
23
857-864
- 6
el-Desouki M, Mohamadiyeh M, al-Rashed R, Othman S, al-Mofleh I.
Features of hepatic cavernous hemangioma on planar and SPECT Tc-99m-labeled red blood
cell scintigraphy.
Clin Nucl Med.
1999;
24
583-589
- 7
Ginsberg F, Slavin J D, Jr., Spencer R P.
Hepatic angiosarcoma: mimicking of angioma on three-phase technetium-99m red blood
cell scintigraphy.
J Nucl Med.
1986;
27
1861-1863
- 8
Ho C L, Yu S C, Yeung D W.
11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
J Nucl Med.
2003;
44
213-221
- 9
Huebner R H, Park K C, Shepherd J E, Schwimmer J, Czernin J, Phelps M E, Gambhir S S.
A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal
cancer.
J Nucl Med.
2000;
41
1177-1189
- 10
Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, Kawabe J, Ochi H.
Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose
in the diagnosis of liver tumors.
Ann Nucl Med.
2000;
14
121-126
- 11
Ji E K, Ryu J S, Kang G H, Moon D H, Auh Y H, Lee H K.
Pelioid-type hepatocellular carcinoma masquerading as a hepatic hemangioma on technetium-99m
red blood cell scintigraphy.
Clin Nucl Med.
2001;
26
33-35
- 12
Karhunen P J.
Benign hepatic tumours and tumour like conditions in men.
J Clin Pathol.
1986;
39
183-188
- 13
Khan M A, Combs C S, Brunt E M, Lowe V J, Wolverson M K, Solomon H, Collins B T, Di
Bisceglie A M.
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.
J Hepatol.
2000;
32
792-797
- 14
Kinkel K, Lu Y, Both M, Warren R S, Thoeni R F.
Detection of hepatic metastases from cancers of the gastrointestinal tract by using
noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
Radiology.
2002;
224
748-756
- 15
Kotzerke J, Schwarzrock R, Krischek O, Wiese H, Hundeshagen H.
Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma,
adenoma, and focal nodular hyperplasia.
J Nucl Med.
1989;
30
1278-1279
- 16
Krause T, Hauenstein K, Studier-Fischer B, Schuemichen C, Moser E.
Improved evaluation of technetium-99m-red blood cell SPECT in hemangioma of the liver.
J Nucl Med.
1993;
34
375-380
- 17
Krug B, Dietlein M, Groth W, Stutzer H, Psaras T, Gossmann A, Scheidhauer K, Schicha H,
Lackner K.
Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma.
Diagnostic comparison with conventional imaging methods.
Acta Radiol.
2000;
41
446-452
- 18
Langenhoff B S, Oyen W J, Jager G J, Strijk S P, Wobbes T, Corstens F H, Ruers T J.
Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor
recurrence after local ablative therapy for liver metastases: a prospective study.
J Clin Oncol.
2002;
20
4453-4458
- 19
Lubbers P R, Ros P R, Goodman Z D, Ishak K G.
Accumulation of technetium-99m sulfur colloid by hepatocellular adenoma: scintigraphic-
pathologic correlation.
AJR Am J Roentgenol.
1987;
148
1105-1108
- 20
Middleton M L.
Scintigraphic evaluation of hepatic mass lesions: emphasis on hemangioma detection.
Semin Nucl Med.
1996;
26
4-15
- 21
Osman M M, Cohade C, Nakamoto Y, Marshall L T, Leal J P, Wahl R L.
Clinically Significant Inaccurate Localization of Lesions with PET/CT: Frequency in
300 Patients.
J Nucl Med.
2003;
44
240-243
- 22
Rabinowitz S A, McKusick K A, Strauss H W.
99mTc red blood cell scintigraphy in evaluating focal liver lesions.
AJR Am J Roentgenol.
1984;
143
63-68
- 23
Rogers J V, Mack L A, Freeny P C, Johnson M L, Sones P J.
Hepatic focal nodular hyperplasia: angiography, CT, sonography, and scintigraphy.
AJR Am J Roentgenol.
1981;
137
983-990
- 24
Rostom A Y, Powe J, Kandil A, Ezzat A, Bakheet S, el-Khwsky F, el-Hussainy G, Sorbris R,
Sjoklint O.
Positron emission tomography in breast cancer: a clinicopathological correlation of
results.
Br J Radiol.
1999;
72
1064-1068
- 25
Schild H, Kreitner K F, Thelen M, Gronninger J, Weber M, Borner N, Storkel J, Eissner D.
[Focal nodular hyperplasia of the liver in 930 patients].
ROFO Fortschr Geb Rontgenstr Nuklearmed.
1987;
147
612-618
- 26
Shih W J, Lee J K, Mitchell B.
False-positive results for hepatic hemangioma on Tc-99m RBC SPECT caused by a liver
metastasis from small-cell lung carcinoma.
Clin Nucl Med.
1996;
21
898-899
- 27
Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S,
Ochi H.
Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for
predicting outcome in patients with hepatocellular carcinoma.
Am J Gastroenterol.
2001;
96
1877-1880
- 28
Teefey S A, Hildeboldt C C, Dehdashti F, Siegel B A, Peters M G, Heiken J P, Brown J J,
McFarland E G, Middleton W D, Balfe D M, Ritter J H.
Detection of primary hepatic malignancy in liver transplant candidates: prospective
comparison of CT, MR imaging, US, and PET.
Radiology.
2003;
226
533-542
- 29
Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K,
Konishi J.
Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional
therapy.
J Nucl Med.
1994;
35
1965-1969
- 30
Trojan J, Schroeder O, Raedle J, Baum R P, Herrmann G, Jacobi V, Zeuzem S.
Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Am J Gastroenterol.
1999;
94
3314-3319
- 31
Wester H J, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau F C, Reubi J C,
Schwaiger M.
PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation
of a novel (18)F-labelled, carbohydrated analogue of octreotide.
Eur J Nucl Med Mol Imaging.
2003;
30
117-122
- 32
Ziessman H A, Silverman P M, Patterson J, Harkness B, Fahey F H, Zeman R K, Keyes J W
Jr.
Improved detection of small cavernous hemangiomas of the liver with high-resolution
three-headed SPECT.
J Nucl Med.
1991;
32
2086-2091
Prof. Dr. Thomas Krause
Abteilung für Nuklearmedizin · Universität Bern · Inselspital
CH 3010 Bern
Telefon: +41/31/6 32 26 10
eMail: thomas.krause@insel.ch
